Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 518 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Rash Clear all
Completed No phase listed Observational

Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life

NCT01835210
View directory record Official record
Conditions
Acne, Quality of Life
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An RCT Evaluating the Efficacy of a Skincare Routine and Acne Supplement on Improving Acne and Other Symptoms of PMS

NCT06018168
View directory record Official record
Conditions
Acne, Premenstrual Syndrome
Interventions
Skincare Routine, MINDBODYSKIN Supplement
Other · Dietary Supplement
Lead sponsor
Clearstem Skincare
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 4 Interventional Results available

Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris

NCT01047189
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin phosphate 1.2% and tretinoin 0.025%, clindamycin 1% gel, tretinoin 0.025% cream
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

NCT01831960
View directory record Official record
Conditions
Acne Vulgaris
Interventions
cortexolone 17α-propionate
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Boise, Idaho • Carmel, Indiana • Clinton Township, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 4 Interventional Results available

Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris

NCT00835198
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone; Tretinoin, Tretinoin
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Strongsville, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne

NCT00964223
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and benzoyl peroxide gel (Duac® Topical Gel), benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Rockville, Maryland • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

NCT02651220
View directory record Official record
Conditions
Acne
Interventions
Epiduo® Forte Gel, Adapalene and Benzoyl Peroxide Gel, placebo gel
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
18
States / cities
Mesa, Arizona • Tucson, Arizona • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 31, 2026, 1:24 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

NCT01148810
View directory record Official record
Conditions
Polymyositis, Dermatomyositis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 2 Interventional

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

NCT00239135
View directory record Official record
Conditions
Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Not applicable Interventional

Clinical Study Evaluating the Safety and Effectiveness of the NIRA Laser M2.1 for the Treatment of Full-Face Wrinkles

NCT07572331
View directory record Official record
Conditions
Skin Ageing, Facial Wrinkles, Acne, Skin Elasticity, Infraorbital Dark Circle Severity, Skin Firmness, UV Spots, Skin Texture, Skin Pores, Brown Spots, Porphyrins, Red Spots
Interventions
NIRA Laser M2.1, Topical
Device · Other
Lead sponsor
NIRA Innovations Inc.
Industry
Eligibility
35 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Beverly, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color

NCT03402893
View directory record Official record
Conditions
Acne Vulgaris, Post Inflammatory Hyperpigmentation
Interventions
ONEXTON Topical Gel
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris

NCT00525499
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ASC-J9 cream, placebo
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Fremont, California • San Diego, California • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 2 Interventional

DOXIL for Consolidation Therapy in Ovarian Cancer.

NCT00248248
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
liposomal doxorubicin
Drug
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 31, 2026, 1:24 AM EDT
Terminated Phase 2Phase 3 Interventional

Lamictal in the Treatment of Post-Herpetic Neuralgia

NCT00295776
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Lamictal in the treatment of Post-Herpetic Neuralgia
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 85 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 1 Interventional Results available

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

NCT03743038
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX101 vehicle, Hydro-alcohol solution
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 3 Interventional Results available

Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus

NCT02573883
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
Fractionated Carbon Dioxide Laser, Clobetasol Propionate 0.05% ointment
Device · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Not applicable Interventional Results available

Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy

NCT01328080
View directory record Official record
Conditions
Acne Keloidalis Nuchae
Interventions
Targeted UV-B
Radiation
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne

NCT03709654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
NB01, Vehicle Control
Biological · Other
Lead sponsor
Naked Biome, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
San Diego, California • Arlington, Texas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Results available

A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris

NCT01347879
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Visonac PDT, Vehicle cream with PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
12 Years to 35 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Oceanside, California • San Diego, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

NCT02267746
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Fabior™), Tazarotene (Actavis), Vehicle foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
14
States / cities
Encino, California • Fremont, California • Brandon, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 2 Interventional

Topical Antiperspirant for Hand-Foot Syndrome

NCT00213993
View directory record Official record
Conditions
Palmar-plantar Erythrodysesthesia
Interventions
antiperspirant
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pimecrolimus Cream for Oral Lichen Planus

NCT00297037
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Pimecrolimus 1% cream
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 31, 2026, 1:24 AM EDT
Completed Phase 4 Interventional Results available

Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women

NCT00616239
View directory record Official record
Conditions
Melasma
Interventions
20-30% Salicylic Acid peels to the right side of the face, 20-30% Salicylic Acid peels to the left side of the face
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 31, 2026, 1:24 AM EDT